Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2129042 | 0.88 | SMN1; SMN2 (0.51) | SMN1; SMN2CYP3A4TDP1KDM4EALDH1A1 | |
| SCHEMBL30592218 | 0.87 | GAA (0.49) | SMN1; SMN2KDM4EALDH1A1GAALMNA | |
| SCHEMBL612669 | 0.87 | GAA (0.49) | SMN1; SMN2KDM4EALDH1A1GAALMNA | |
| SCHEMBL31644242 | 0.84 | SMN1; SMN2 (0.52) | SMN1; SMN2CYP3A4TDP1KDM4EALDH1A1 | |
| SCHEMBL24773784 | 0.84 | SMN1; SMN2 (0.51) | SMN1; SMN2CYP3A4TDP1KDM4EALDH1A1 | |
| SCHEMBL25246581 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2CYP3A4TDP1KDM4EALDH1A1 | |
| SCHEMBL612852 | 0.84 | SMN1; SMN2 (0.52) | SMN1; SMN2CYP3A4TDP1KDM4EALDH1A1 | |
| SCHEMBL25136864 | 0.84 | KDM4E (0.51) | SMN1; SMN2KDM4EALDH1A1GAALMNA | |
| SCHEMBL25151051 | 0.83 | CYP3A4 (0.47) | SMN1; SMN2CYP3A4KDM4EALDH1A1HPGD | |
| SCHEMBL7362801 | 0.83 | POLB (0.60) | SMN1; SMN2CYP3A4TDP1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552771-B2 | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | CELGENE CORPORATION (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4587127-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics Incorporated (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20240270714-A1 | Carboxylic Acid Containing Azetidinyl Compounds for the Treatment of Neurodegenerative Diseases | CELGENE CORPORATION (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240165244-A1 | BRM Targeting Compounds And Associated Methods Of Use | PRELUDE THERAPEUTICS INCORPORATED | 2024-05-23 | — | — | US | disclosed |
| EP-4371982-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-4355729-A1 | AZETIDINYL COMPOUNDS COMPRISING A CARBOXYLIC ACID GROUP FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Celgene Corporation (US) | 2024-04-24 | — | — | EP | disclosed |
| EP-3583096-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| WO-2024059806-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-03-21 | — | — | WO | disclosed |
| US-11919879-B2 | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | CELGENE CORPORATION (US) | 2024-03-05 | — | — | US | disclosed |
| CN-117500785-A | Azetidinyl-containing carboxylic acid compounds for the treatment of neurodegenerative diseases | 细胞基因公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20090048238-A1 | NOVEL BIARYL DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20090042852-A1 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| EP-1942890-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2008-07-16 | — | — | EP | disclosed |
| EP-1896023-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2008-03-12 | — | — | EP | disclosed |
| EP-1836189-A1 | NOVEL PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006073361-A9 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
| WO-2006138350-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006138259-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006073361-A1 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| US-20050277668-A1 | viricide, antiinflammatory agent; autoimmune diseases; protective effects against infection of target cells by a human immunodeficiency virus (HIV); 6-Chloro-N-((R)-3-{4-[(4-methoxy-phenyl)-(4-methyl-pyridin-3-ylmethyl)-amino]-piperidin-1-yl}-butyl)-2,4-dimethyl-nicotinamide | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277668-A1 | viricide, antiinflammatory agent; autoimmune diseases; protective effects against infection of target cells by a human immunodeficiency virus (HIV); 6-Chloro-N-((R)-3-{4-[(4-methoxy-phenyl)-(4-methyl-pyridin-3-ylmethyl)-amino]-piperidin-1-yl}-butyl)-2,4-dimethyl-nicotinamide | CCR5, CCR2, CXCR3 | SMN1; SMN2 3475/4885CYP3A4 3245/4885TDP1 2443/4885 |
| US-20090042852-A1 | Novel Pyridine Compounds | P2RY12, P2RY11, P2RY1 | SMN1; SMN2 3557/4885CYP3A4 801/4885TDP1 1481/4885 |
| US-20240165244-A1 | BRM Targeting Compounds And Associated Methods Of Use | ABCG2, BRIX1, MRPS28 | SMN1; SMN2 2829/4885CYP3A4 847/4885TDP1 4412/4885 |
| US-20090048238-A1 | NOVEL BIARYL DERIVATIVES | CCR3, CCRL2, CCR2 | SMN1; SMN2 3658/4885CYP3A4 563/4885TDP1 4662/4885 |
| US-20240270714-A1 | Carboxylic Acid Containing Azetidinyl Compounds for the Treatment of Neurodegenerative Diseases | S1PR5, LPAR5, S1PR2 | SMN1; SMN2 15/4885CYP3A4 4646/4885TDP1 1735/4885 |
| US-11919879-B2 | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | S1PR5, LPAR5, S1PR2 | SMN1; SMN2 15/4885CYP3A4 4646/4885TDP1 1735/4885 |
| US-12552771-B2 | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | S1PR5, CLN6, SNCA | SMN1; SMN2 12/4885CYP3A4 3718/4885TDP1 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.